[The effect of biologically active compounds on lysosome fusion with phagosomes and the F-actin content in mouse peritoneal macrophages and on the status of the lysosomal membranes in mouse hepatocytes].
Effects of biologically active compounds bilirubin (BR, 0.1 and 0.2 mM), chelerythrine (CR, 0.1 and 0.5 mM) and farmorubicin (FR, 0.6 and 6.0 mM) on the phagosome-lysosome fusion (P-LF) were studied using fluorescent dye acridine orange for lysosomal labelling and yeast cells as a target. To investigate mechanisms of these effects, changes in fluidity of lysosomal membranes from murine liver were studied by measuring of fluorescence intensity, lifetime and polarization of the fluorescent membrane probes: DPH (1,6-diphenyl-1,3,5-hexatriene) and TMA-DPH [1-(4-triphenylamino)-6-phenyl-1,3,5-hexatriene] incorporated in isolated murine liver lysosomes. In order to characterize the induced cytoskeleton changes, the F-actin content in murine peritoneal macrophages was determined. It was found that all three compounds tested enhanced P-LF. Our results demonstrate that BR induces a decrease in DPH and TMA-DPH fluorescence polarization, FR increases DPH and TMA-DPH fluorescence polarization, and CR causes an increase in TMA-DPH fluorescence polarization in lysosomal membranes. All the three compounds increase F-actin content in peritoneal macrophages. Thus, the action of BR extended on P-LF is associated with increasing lysosomal membranes fluidity and cytoskeleton changes. The enhancement of P-LF under the action of FR and CR can be most likely explained by changes of cytoskeleton.
Mozhenok
T P
TP
Institute of Cytology, Russian Academy of Sciences, St. Petersburg.
Beliaeva
T N
TN
Bulychev
A G
AG
Kuznetsova
I M
IM
Leont'eva
E A
EA
Faddeeva
M D
MD
D000199:Actins / Q000187:drug effects* / Q000648:ultrastructure; D000470:Alkaloids; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D053119:Benzophenanthridines; D001663:Bilirubin / Q000494:pharmacology*; D015251:Epirubicin / Q000494:pharmacology*; D005456:Fluorescent Dyes; D007425:Intracellular Membranes / Q000187:drug effects* / Q000648:ultrastructure; D008099:Liver / Q000187:drug effects* / Q000648:ultrastructure; D008247:Lysosomes / Q000187:drug effects* / Q000648:ultrastructure; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000648:ultrastructure; D008561:Membrane Fusion / Q000187:drug effects*; D051379:Mice; D008810:Mice, Inbred C57BL; D010588:Phagosomes / Q000187:drug effects* / Q000648:ultrastructure; D010617:Phenanthridines / Q000494:pharmacology*
D000199:Actins; D000470:Alkaloids; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D053119:Benzophenanthridines; D005456:Fluorescent Dyes; D010617:Phenanthridines; D015251:Epirubicin; C016299:chelerythrine; D001663:Bilirubin
Vliianie biologicheski aktivnykh soedineniĭ na sliianie lizosom s fagosomami i soderzhanie F-aktina v peritoneal'nykh makrofagakh myshi i na sostoianie lizosomnykh membran gepatotsitov myshi.